Medical device maker Medtronic, Inc. (MDT), Wednesday said it will expand its CURE-AF or Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation or AF clinical program with a post-market study into Europe and Canada. CURE-AF is being conducted in United States to secure Food and Drug Administration's approval for the drug Cardioblate for investigational treatment of AF patients.
Minneapolis, Minnesota-based Medtronic said the program will now collect post-market data internationally on the efficacy of irrigated cardiac ablation with radiofrequency -RF energy in AF patients.
In the CURE-AF investigation procedure, Medtronic's Cardioblate System will be used to create a pattern of transmural lesions, which span the full thickness of heart tissue that would be instrumental in restoring normal heart rhythm. The investigation procedure is an open heart surgery for the repair of valve or for coronary Artery Bypass Graft-CABG.
The company said Cardioblate surgical ablation system is currently indicated for cardiac tissue ablation, and has been used in more than 90,000 procedures worldwide.
MDT is currently trading at $33.99, down $0.08 or 0.26%, on a volume of 3.668 million shares.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.